Breast Cancer

Explore the unique challenges faced by young patients with breast cancer and learn how innovative navigation programs are bridging gaps in care and empowering patients to thrive.

We are pleased to announce the release of our next issue of Clinical Trials to Clinical Practice. This article provides expert commentary from Joyce A. O’Shaughnessy, MD, on the use of endocrine therapy with or without adjuvant abemaciclib for patients with high-risk, hormone receptor (HR)-positive, HER2-negative early breast cancer.

The Navigator Guide: Walking With a Patient Down the Early Breast Cancer Path is a resource that oncology nurses and navigators can use to assist patients and caregivers in the fight against early-stage breast cancer. Oncology nurses and navigators guide patients through their treatment journey from time of diagnosis into survivorship, providing education, resources, and support.

In partnership with Daiichi Sankyo, this roadmap is intended to provide a comprehensive overview and educational resource for advanced practice providers (Nurse Practitioner, Pharmacist, Physician Assistant) and oncology nurse navigators on HER2+/HER2-low breast cancer including key considerations for treatment, setting upfront expectations, and adverse event management.

Navigating the antibody–drug conjugate treatment landscape for patients with HER2-positive or HER2-low metastatic breast cancer.

This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study.

Please join Sara Tolaney, MD, MPH, Dana-Farber Cancer Center, Boston, MA; Erica Stringer-Reasor, MD, University of Alabama, Birmingham; and Matteo Lambertini, MD, PhD, University of Genoa, Italy, as they provide expert commentary on key breast cancer abstracts presented at the 2023 ASCO Annual Meetings that will impact young women with ER+/HER2- breast cancer.

The Academy of Oncology Nurse & Patient Navigators (AONN+) and Eli Lilly and Company Medical Affairs are pleased to present a live webinar designed to facilitate conversations with patients regarding adherence to breast cancer treatments. Attendees will have an opportunity to participate in a live Q&A following the presentation.

Oral oncolytic drugs have a multitude of benefits for patients, including ease of use, improved quality of life, fewer clinic visits, and no need for IV therapy.